Infectious Diseases

The FDA today announces the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.

AMA has adopted a multi-prong strategy to try to counter lies while holding the person responsible to professional review.

The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee unanimously voted recently to recommend both the Pfizer-BioNTech and Moderna COVID-19 vaccines for individuals aged 6 months and older.

COVID-19 vaccination during pregnancy may reduce infants’ risk of infection during the early months of life, according to a recent study.

In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.

Kenneth J. Tomecki, MD, discussed the clinical relevance of sexually transmitted diseases to dermatology and outlined what to look for and how to treat various conditions at the 2022 Fall Clinical Dermatology Conference for PAs & NPs.

GSK plc today announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.

Most children outgrow an adverse drug reaction to oral antibiotics, according to an Icelandic study.

A survey saw that of teenagers who sought care in the ED and were prescribed outpatient treatment, fewer than half who received an STI diagnosis filled their prescriptions.

Paul A. Offit, MD, pulls back the curtain on medical discoveries in "You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation"

Study links inappropriate, off-guideline antibiotics to increased, avoidable allergic and adverse events in children.

Decreasing cases of chlamydia may offer false hope in light of decreased screening.

A look at what the Contemporary Pediatrics® team covered this week.

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.

Pfizer-BioNTech reports strong immune response, high efficacy, and favorable safety in third dose of the COVID-19 vaccine.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

A look at what the Contemporary Pediatrics® team covered this week.

Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief of Contemporary Pediatrics, shares her insights on the recent outbreaks of hepatitis in children.

New data suggest pediatric patients with a history of cardiac arrest are highly susceptible to hospitalization if infected with SARS-CoV-2.

Nearly 9 million symptomatic cases also avoided.

Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.

A comparison of COVID-19 PCR tests and rapid self-tests found self-tests to be highly accurate and user-friendly for children.

Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.

Active immunization of pregnant women with investigational vaccine protected infants from RSV from birth through at least 6 months.

Children living with HIV had a similar immune response to mRNA COVID-19 vaccination as children without HIV.